As the pandemic has continued to impact the world, there has been a growing focus on the importance of developing new treatments for a range of diseases, including those affecting the brain. Lantern Pharma, a clinical-stage biopharmaceutical company, has developed artificial intelligence (AI) algorithms that can predict the blood-brain-barrier permeability of any compound. Lantern Pharma’s AI algorithms have the potential to significantly impact the medical industry by improving the efficiency and effectiveness of drug development, says GlobalData, a leading data and analytics company.

Kamilla Kan, Medical Analyst at GlobalData, comments: “The development of these algorithms has been influenced by the COVID-19 pandemic, which has highlighted the urgent need for innovative medical solutions. This breakthrough technology has the potential to revolutionize drug development and improve treatment options for a range of neurological and psychiatric disorders.”

According to GlobalData estimates, the total AI market will be worth $383.3 billion in 2030, registering a 21% compound annual growth rate between 2022 and 2030.

Kan concludes: “By predicting the blood-brain-barrier permeability of compounds, Lantern Pharma’s AI algorithms can help drug developers to target their efforts more effectively and develop treatments that are more likely to be successful. As the medical industry continues to face unprecedented challenges, it is vital that innovative solutions like these algorithms are developed to ensure that patients receive the best possible care.”